摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

(imidazolium)[trans-RuCl4(DMSO)2] | 302838-33-1

中文名称
——
中文别名
——
英文名称
(imidazolium)[trans-RuCl4(DMSO)2]
英文别名
[ImH][trans-RuCl4(dmso-S)2]
(imidazolium)[trans-RuCl4(DMSO)2]化学式
CAS
302838-33-1
化学式
C3H5N2*C4H12Cl4O2RuS2
mdl
——
分子量
468.238
InChiKey
BOTZQJVZNJAAJB-UHFFFAOYSA-K
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    None
  • 重原子数:
    None
  • 可旋转键数:
    None
  • 环数:
    None
  • sp3杂化的碳原子比例:
    None
  • 拓扑面积:
    None
  • 氢给体数:
    None
  • 氢受体数:
    None

反应信息

  • 作为反应物:
    描述:
    (imidazolium)[trans-RuCl4(DMSO)2]氧化亚氮硝基甲烷 为溶剂, 以30%的产率得到[ImH][trans-RuCl4(dmso-O)(NO)]
    参考文献:
    名称:
    新钌二甲基亚砜亚硝酰基的合成,结构,光谱和电化学表征。
    摘要:
    氯化钌(II)和钌(III)-二甲基亚砜前体与抗转移药物[ImH] [trans-RuCl(4)(dmso-S)(Im)]的反应性(NAMI-A,Im =研究了咪唑(dmso =二甲基亚砜)对NO的影响。用气态NO处理[(dmso)(2)H] [反式RuCl(4)(dmso-S)(2)]和mer-RuCl(3)(dmso)(3) )H] [反式RuCl(4)(dmso-O)(NO)](1)和mer,cis-RuCl(3)(dmso-O)(2)(NO)(2)。因此,强π-受体NO的配位诱导了dmso反式的S-O键异构化,从而避免了对pi-电子的竞争。在受光保护的硝基甲烷溶液中,配合物2与两个异构体mer-RuCl(3)(dmso-S)(dmso-O)(NO)(3)缓慢平衡,其中NO转化为Cl和mer-RuCl(3 )(dmso-S)(dmso-O)(NO)(4),其中NO转化为dmso-O;
    DOI:
    10.1021/ic011291v
  • 作为产物:
    描述:
    [(DMSO)2H][trans-Ru(DMSO)2Cl4] 、 Na[trans-RuCl4(DMSO)2]咪唑盐酸盐 以 not given 为溶剂, 生成 (imidazolium)[trans-RuCl4(DMSO)2]
    参考文献:
    名称:
    Synthesis, Characterization, and in Vitro Evaluation of a Potentially Selective Anticancer, Mixed-Metal [Ruthenium(III)−Platinum(II)] Trinuclear Complex
    摘要:
    A new type of mixed-metal trinuclear complex containing platinum(II) and ruthenium(III) fragments that resemble both cisplatin and NAMI-A has been synthesized and characterized by IR, H-1 NMR, elemental analysis, and X-ray crystallography. The water-soluble compound Na-2{trans,cis,trans-[(RuCl4)-Cl-III(DMSO-S)(mu-pyz)](2)(PtCl2)-Cl-II} (AH-197, pyz = pyrazine) was assessed for its effects on DNA mobility and toxicity against human cancer cell lines. When compared to cisplatin and KP-1019 (which structurally resembles NAMI-A), IC50 results showed that AH-197 had an intermediate toxicity. When this data was coupled with a subsequent COMPARE evaluation (standard COMPARE queries resulted in insignificant correlation coefficients (<0.70) while very low COMPARE correlation coefficients were found in the matrix queries as well), AH-197 yielded a correlation coefficient of 0.19 when compared to cisplatin and 0.25 when compared to KP1019 indicating that AH-197 has a unique behavior.
    DOI:
    10.1021/ic062419h
点击查看最新优质反应信息